Articles
30 April 2012
Vol. 34 No. 2 (2012)
https://doi.org/10.4081/pmc.2012.67

Good response with zinc acetate monotherapy in an adolescent affected by severe Wilson disease

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Haemolytic anaemia, Wilson disease, zinc acetate
1267
Views
1119
Downloads

Authors

M.G. Marazzi
mgraziamarazzi@ospedale-gaslini.ge.it
Department of Paediatrics, University of Genoa, Infectious Diseases Unit, G. Gaslini Children’s Hospital, Genova, Italy.
S. Giardino
Paediatric Haematology and Oncology Unit, G. Gaslini Children’s Hospital, Genova, Italy.
C. Dufour
Paediatric Haematology and Oncology Unit, G. Gaslini Children’s Hospital, Genova, Italy.
M. Serafino
Department of Paediatrics, University of Genoa, Genova, Italy.
D. Sperlì
Department of Paediatrics, Azienda Ospedaliera di Cosenza, Cosenza, Italy.
R. Giacchino
Infectious Diseases Unit, G. Gaslini Children’s Hospital, Genova, Italy.
We describe a 17-year-old girl with haemolytic anaemia as presentation of Wilson disease. The diagnosis was based on the findings of < 20 mg/dl ceruloplasmin serum level, Kayser-Fleischer ring and Coombs-negative haemolytic anaemia. Genetic testing revealed the presence of the H1069Q heterozygous mutation. The patient was treated with Zinc acetate monotherapy, with good response, maintened after 22 months. This case emphasizes the importance of recognizing atypical clinical presentation of Wilson disease, which must always be considered in patients with Coombs-negative haemolytic anaemia. The good clinical response to treatment with zinc acetate monotherapy in our case might lend to consider the use of zinc monotherapy as initial therapy also in symptomatic patients with Wilson disease under close clinical observation. Clinical trials are needed to provide evidence for use of zinc monotherapy as first-line therapy in symptomatic patients with Wilson disease.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite



Good response with zinc acetate monotherapy in an adolescent affected by severe Wilson disease. (2012). La Pediatria Medica E Chirurgica, 34(2). https://doi.org/10.4081/pmc.2012.67

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.